Mathematical Models & Estimating Flu Infections/Hospitalizations
Returning guest, Dr. Joaquin Mould-Quevedo, Global HEOR & Value Strategy Director at Seqirus, one of the world’s largest influenza vaccine providers, discusses the benefits of real-world evidence (RWE) to assess vaccine economic impacts in influenza. He talks about the economic burden of seasonal flu on global health care systems, the role of health economics and outcomes research (HEOR) and economic modeling in vaccines, ways RWE and HEOR support National Immunization Technical Advisory Groups (NITAGs) around the world, how data is leveraged for country-specific applications, and more.
Dr. Joaquin Mould-Quevedo is the Global Pricing and Health Economics Director at Seqirus, a global leader in seasonal influenza prevention and pandemic influenza preparedness. At Seqirus, Joaquin provides leadership on Seqirus’ market access strategies to ensure broad payer coverage for Seqirus products. Prior to joining Seqirus, Joaquin was the Global Health Economics and Outcomes Research Director at Bayer Pharmaceuticals, overseeing its real-world evidence strategy within the oncology division. Joaquin was also previously with Pfizer and held the title of Health Economics and Outcomes Research Senior Director for Latin America and Primary Care.
Joaquin received his bachelor’s in economics from the University del Pacifico in Lima, Peru before earning his master’s in business administration from Paris University and his PhD in applied economics from the University of Alicante in Spain. Additionally, Joaquin has also developed advanced courses in pharmacoeconomics at the University of York in England.
Prior to joining the pharmaceutical industry, Joaquin worked at the Mexican Social Security Institute as a Health Economics researcher and was also President for the 2012-2014 Health Technology Producers Committee at the Latin American ISPOR Consortium.
Joaquin has performed over 200 pharmacoeconomics and outcomes research assessments and has over 70 publications of health economics and outcomes research topics in a variety of international, peer-reviewed journals. He has completed over 175 presentations at International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Meetings.
